Finch Therapeutics Group Inc (FNCH)
2.36
-0.13
(-5.22%)
USD |
NASDAQ |
May 03, 16:00
2.36
0.00 (0.00%)
After-Hours: 18:01
Finch Therapeutics Group Enterprise Value: -21.13M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | -21.13M |
| May 01, 2024 | -21.42M |
| April 30, 2024 | -21.53M |
| April 29, 2024 | -21.43M |
| April 26, 2024 | -21.40M |
| April 25, 2024 | -21.53M |
| April 24, 2024 | -21.43M |
| April 23, 2024 | -20.65M |
| April 22, 2024 | -21.41M |
| April 19, 2024 | -21.53M |
| April 18, 2024 | -21.33M |
| April 17, 2024 | -21.08M |
| April 16, 2024 | -20.15M |
| April 15, 2024 | -21.52M |
| April 12, 2024 | -21.86M |
| April 11, 2024 | -21.35M |
| April 10, 2024 | -21.19M |
| April 09, 2024 | -21.18M |
| April 08, 2024 | -21.59M |
| April 05, 2024 | -21.59M |
| April 04, 2024 | -21.45M |
| April 03, 2024 | -21.27M |
| April 02, 2024 | -21.17M |
| April 01, 2024 | -21.03M |
| March 28, 2024 | -20.95M |
| Date | Value |
|---|---|
| March 27, 2024 | -20.48M |
| March 26, 2024 | -20.88M |
| March 25, 2024 | -20.79M |
| March 22, 2024 | -21.00M |
| March 21, 2024 | -20.93M |
| March 20, 2024 | -20.72M |
| March 19, 2024 | -20.64M |
| March 18, 2024 | -20.76M |
| March 15, 2024 | -21.02M |
| March 14, 2024 | -21.11M |
| March 13, 2024 | -21.01M |
| March 12, 2024 | -20.80M |
| March 11, 2024 | -19.63M |
| March 08, 2024 | -21.11M |
| March 07, 2024 | -21.19M |
| March 06, 2024 | -21.11M |
| March 05, 2024 | -21.11M |
| March 04, 2024 | -20.88M |
| March 01, 2024 | -20.76M |
| February 29, 2024 | -20.79M |
| February 28, 2024 | -20.94M |
| February 27, 2024 | -21.05M |
| February 26, 2024 | -21.05M |
| February 23, 2024 | -21.24M |
| February 22, 2024 | -21.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-53.41M
Minimum
Dec 23 2022
907.23M
Maximum
Mar 19 2021
135.99M
Average
-6.091M
Median
Oct 21 2022
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals Inc | 2.374B |
| Vanda Pharmaceuticals Inc | -118.99M |
| Sage Therapeutics Inc | 71.67M |
| BioSig Technologies Inc | 19.66M |
| Palisade Bio Inc | -6.078M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.041M |
| Total Expenses (Quarterly) | 4.681M |
| EPS Diluted (Quarterly) | -1.89 |
| Earnings Yield | -2.02K% |
| Normalized Earnings Yield | -2081.58 |